CNCB (Hong Kong) Investment Limited

CNCB (Hong Kong) Investment Limited is a private equity firm headquartered in Hong Kong, specializing in investments across various sectors and stages. The firm focuses on private equity, venture capital, and real estate investments, targeting early-stage to late-stage companies, including pre-IPO and buyout opportunities. Their geographical focus includes China, Hong Kong, the United States, and Singapore, with a diverse industry portfolio encompassing healthcare, life sciences, technology, consumer goods, financial services, energy, infrastructure, media, telecommunications, retail, education, transportation, real estate, agriculture, and manufacturing.

The firm manages multiple funds, including fixed income and private equity funds, with assets under management totaling approximately HK$1.0 billion as of September 30, 2022. Notable investments include Broncus Holding Corporation, a pioneer in interventional pulmonology, and Simcere Pharmaceutical Group Limited, an innovative pharmaceutical company. CNCB (Hong Kong) Investment Limited's investment strategy emphasizes a comprehensive approach, leveraging its international management standards and strong ties with its parent company, China CITIC Bank Corporation Limited, to offer effective and timely financial solutions to its portfolio companies.

With a team of qualified international banking professionals, the firm is committed to international standards, business excellence, and corporate governance. Its strategic collaboration with China CITIC Bank Corporation Limited enhances its market connectivity and depth of knowledge in the PRC, enabling the firm to provide one-stop cross-border financial solutions to its clients. This synergy supports the firm's mission to drive growth and value creation in its portfolio companies across diverse industries and stages.